Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole

Therapeutic Advances in Psychopharmacology

Volumn 7, Issue 1, 2017, Pages 29-41

  Frankel, Joshua S ^a   Schwartz, Thomas L ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

antipsychotic; aripirazole; brexpiprazole; cariprazine; dopamine partial agonist

Indexed keywords

ARIPIPRAZOLE; BREXPIPRAZOLE; CARIPRAZINE;

ABDOMINAL PAIN; AKATHISIA; ANXIETY DISORDER; AUTISM; BINDING AFFINITY; BIPOLAR DISORDER; BIPOLAR MANIA; BLURRED VISION; CLINICAL EFFECTIVENESS; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPEPSIA; DYSTONIA; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PARKINSONISM; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; TACHYCARDIA; VOMITING; XEROSTOMIA;

EID: 85032572179     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125316672136     Document Type: Review

References (48)

1. Actavis (2015) VRAYLAR™ (Cariprazine) Capsules, for Oral Use (prescribing Information). Available at: http://pi.actavis.com/data_stream.asp?product_group=2028&p=pi (accessed 6 December 2015).
2. Adams D., Close S., Farmen M., Downing Ann Catherine M., Breier A., Houston J., (2008) Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately Caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol 23: 267–274.
3. Alkermes (2015) ARISTADA™ (Aripiprazole Lauroxil) Extended Release Injectable Suspension for Intramuscular Use (Prescribing Information). Available at: http://www.aristada.com/hcp/ARISTADA-prescribing-information.pdf (accessed 6 December 2015).
4. Andrezine R., Josiassen R., Marcus R., Oren D., Manos G., Stock E.. (2006) Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology 188: 281–292.
5. Berman R., Marcus R., Swanink R., McQuade R., Carson W., Corey-Lisle P.. (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68: 843–853.
6. Calabrese J., Keck P., Starace A., Lu K., Ruth A., Laszlovszky I.. (2015) Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 76: 284–292.
7. Citrome L., (2005) The ABC’s of dopamine receptor partial agonists – aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract 69: 1211–1220.
8. Citrome L., (2015) Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 69: 978–997.
9. Correll C., Skuban A., Ouyang J., Hobart M., Pfister S., McQuade R.. (2015) Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 172: 870–880.
10. Cutler A., Marcus R., Hardy S., O’Donnell A., Carson W., McQuade R., (2006) The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr 11: 691–702.
11. Debelle M., Nemeth G., Szalai E., Szamtmari B., Harsanyi J., Barabassy A.. (2015) Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol 25: S510.
12. Durgam S., Cutler A., Lu K., Migliore R., Ruth A., Laszlovzky I.. (2015a) Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry 76: e1574–e1582.
13. Durgam S., Cutler A., Lu K., Migliore R., Ruth A., Laszlovzky I.. (2015b) Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol 35: 367–373.
14. Durgam S., Starace A., Li D., Migliore R., Ruth A., Németh G.. (2014) An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res 152: 450–457.
15. Durgam S., Starace A., Li D., Migliore R., Ruth A., Nemeth G.. (2015c) The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord 17: 63–75.
16. Findling R., Correll C., Nyilas M., Forbes R., McQuade R., Jin N.. (2013) Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord 15: 138–149.
17. Findling R., Robb A., Nyilas M., Forbes R., Jin N., Ivanova S.. (2008) A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165: 1432–1441.
18. Gobert A., Rivet J., Lejeune F., Newman-Tancredi A., Adhumeau-Auclair A., Nicolas J.. (2000) Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36: 205–221.
19. Gross G., Drescher K., (2012) The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol 213: 167–210.
20. Hedlund P., Huitron-Resendiz S., Henriksen S., Sutcliffe J., (2005) 5-HT7 Receptor inhibition and inactivation induce antidepressant-like behavior and sleep pattern. Biol Psychiatry 58: 831–837.
21. Kane J., Carson W., Saha A., McQuade R., Ingenito G., Zimbroff D.. (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63: 763–771.
22. Kane J., Peters-Strickland T., Baker R., Hertel P., Eramo A., Jin N.. (2014) Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 75: 1254–1260.
23. Kane J., Sanchez R., Perry P., Jin N., Johnson B., Forbes R.. (2012) Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 73: 617–624.
24. Kane J., Skuban A., Ouyang J., Hobart M., Pfister S., McQuade R.. (2015) A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 164: 127–135.
25. Keck P., Marcus R., Tourkodimitris S., Ali M., Liebeskind A., Saha A.. (2003) A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160: 1651–1658.
26. Keck P., Orsulak P., Cutler A., Sanchez R., Torbeyns A., Marcus R.. (2009) Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 112: 36–49.
27. Kiss B., Horvath A., Nemethy Z., Schmidt E., Laszlovszky I., Bugovics G.. (2010) Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 333: 328–340.
28. Lehman A., Lieberman J., Dixon L., McGlashan T., Miller A., Perkins, D. (2004) Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd ed. Available at: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia.pdf (accessed 14 January 2016).
29. McEvoy J., Daniel D., Carson W., McQuade R., Marcus R., (2007) A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 41: 895–905.
30. Marcus R., McQuade R., Carson W., Hennicken D., Fava M., Simon J.. (2008) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28: 156–165.
31. Marcus R., Owen R., Kamen L., Manos G., McQuade R., Carson W.. (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48: 1110–1119.
32. Meltzer H., Risinger R., Nasrallah H., Du Y., Zummo J., Corey L.. (2015) A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry 76: 1085–1090.
33. Otsuka (2014) Abilify (Aripiprazole) Tablets, Abilify Discmelt (Aripiprazole) Orally Disintegrating Tablets, Abilify (Aripiprazole) Oral Solution, Abilify (Aripiprazole) Injection for Intramuscular Use Only (Prescribing Information). Available at: http://www.otsuka-us.com/Documents/Abilify.PI.pdf (accessed 6 December 2015).
34. Otsuka (2015a) Abilify Maintena (Aripiprazole) Extended Release Injectable Suspension for Intramuscular Use (Prescribing Information). Available at: http://www.otsuka-us.com/Products/Documents/Abilify.M.PI.pdf (accessed 6 December 2015).
35. Otsuka (2015b) Rexulti (Brexpiprazole) Tablets, for Oral Use (Prescribing Information). Available at: http://www.otsuka-us.com/Products/Documents/Rexulti.PI.pdf (accessed 6 December 2015).
36. Otsuka (2015c) Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder. Available at: https://clinicaltrials.gov/ct2/show/NCT01727700 (accessed 16 October 2015).
37. Owen R., Sikich L., Marcus R., Corey-Lisle P., Manos G., McQuade R.. (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124: 1533–1540.
38. Potkin S., Saha A., Kujawa M., Carson W., Ali M., Stock E.. (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60: 681–690.
39. Sachs G., Greenberg W., Starace A., Lu K., Ruth A., Laszlovszky I.. (2015) Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord 174: 296–302.
40. Sachs G., Sanchez R., Marcus R., Stock E., McQuade R., Carson W.. (2006) Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 20: 536–546.
41. Stahl S., (2013) Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 4th ed. Cambridge: Cambridge University Press.
42. Thase M., Youakim J., Skuban A., Hobart M., Augustine C., Zhang P.. (2015a) Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 76: 1224–1231.
43. Thase M., Youakim J., Skuban A., Hobart M., Zhang P., McQuade R.. (2015b) Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 76: 1232–1240.
44. Tran-Johnson T., Sack D., Marcus R., Auby P., McQuade R., Oren D., (2007) Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 68: 111–119.
45. Vieta E., T’joen C., McQuade R., Carson W., Marcus R., Sanchez R.. (2008) Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 165: 1316–1325.
46. Yoo H., Joung Y., Lee J., Song D., Lee Y., Kim J.. (2013) A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry 74: e772–e780.
47. Young A., Oren D., Lowy A., McQuade R., Marcus R., Carson W.. (2009) Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry 194: 40–48.
48. Zimbroff D., Marcus R., Manos G., Stock E., McQuade R., Auby P.. (2007) Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 27: 171–176.